Coherus Oncology (CHRS) opened Q1 2026 with total revenue of US$12.3 million and a basic EPS loss of US$0.27, presenting a clear picture of a business still in investment mode. Over recent quarters the company reported revenue of US$7.7 million in Q4 2024, US$7.6 million in Q1 2025, US$10.3 million in Q2 2025, US$12.7 million in Q4 2025, and US$12.3 million in the latest quarter. Over the same period, basic EPS losses moved from US$0.40 in Q4 2024 to US$0.41 in Q1 2025, then around US$0.38 through mid 2025 and US$0.27 in Q1 2026. For investors, a key question from this print is whether the current revenue base can eventually carry the weight of ongoing losses so margins have room to improve.

See our full analysis for Coherus Oncology.

With the quarter set out in numbers, the next step is to compare these results with the dominant narratives around Coherus Oncology to see which views the latest margins support and which they challenge.

Losses still heavy at US$36.9 million

• Q1 2026 net income excluding extra items was a loss of US$36.9 million on revenue of US$12.3 million, compared with losses between about US$44 million and US$47 million across each quarter of 2025 on lower revenue earlier in that period.
• Consensus narrative talks about strong future revenue growth and improved margins, yet current quarterly losses and a trailing 12 month loss of US$172.7 million mean the business is still a long way from the earnings profile analysts use in their 2029 scenarios.
  • Analysts are assuming revenue growth of 64.3% a year over the next 3 years, while the latest quarter shows a much smaller revenue base of US$12.3 million and continued losses.
  • The same narrative looks for earnings of US$24.0 million by 2029, which contrasts with the recent history of quarterly losses above US$36.9 million and a trailing 12 month loss above US$170 million.

Revenue base still modest at US$46.9 million LTM

• On a trailing 12 month view to Q1 2026, Coherus Oncology generated US$46.9 million of total revenue. This sets the current sales base that any future growth percentages will build from.
• Bulls focus on potential revenue expansion from LOQTORZI and pipeline assets, but the current revenue level and ongoing losses highlight how dependent that bullish story is on future execution rather than what is already visible in these figures.
  • For example, bullish scenarios reference large oncology market opportunities. However, the latest quarterly revenue of US$12.3 million and trailing 12 month revenue below US$50 million show that commercialization is still early in scale terms.
  • Forecast revenue growth of 38.5% a year is cited as a reward. At the same time, the trailing 12 month loss of US$172.7 million means a larger revenue base would still need to cover substantial operating costs before earnings can turn positive.

Bulls argue that today’s small revenue base could be the starting point for much larger sales if key drugs ramp as expected. It can therefore be useful to see how that optimistic path compares to the detailed Bull Case narrative for Coherus Oncology 🐂 Coherus Oncology Bull Case

Valuation gap vs DCF fair value and price target

• At a share price of US$1.71, Coherus Oncology is described as trading at a P/S of 5.6x versus a peer average of 42.1x and a US Biotechs industry average of 9.7x, and also far below a DCF fair value of about US$30.74 per share.
• Bears point to heavy losses and dilution to question how much comfort that apparent discount really offers, and these Q1 numbers give them several data points to reference.
  • The trailing 12 month loss of US$172.7 million and the expectation that the company will remain unprofitable over the next 3 years sit uneasily beside an analyst price target of US$7.80, which is well above the current US$1.71 share price.
  • Major shareholder dilution over the past year is flagged as a key risk. If further funding is needed to support a business that is still loss making each quarter, any valuation upside implied by P/S comparisons and DCF fair value may be spread over a growing share count.

Skeptics argue that losses, dilution and execution risk all need to be weighed against any discount to fair value. This is exactly what the detailed Bear Case narrative for Coherus Oncology is designed to unpack 🐻 Coherus Oncology Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Coherus Oncology on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With mixed views on losses, revenue and valuation running through this update, it is worth checking the underlying data yourself and moving quickly to shape your own view, starting with the 3 key rewards and 2 important warning signs.

Explore Alternatives

Coherus Oncology is still working through heavy quarterly losses and a modest US$46.9 million revenue base, so profitability and financial resilience remain key concerns.

If you want ideas with fewer balance sheet question marks and potentially stronger financial footing, start comparing options using the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.